National & Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, Liver and Spleen Diseases Research Center, Precision Medical Institute, The Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Bio-evidence Science Academy, Xi'an Jiaotong University, Xi'an, China.
Biochem Biophys Res Commun. 2021 Jan 1;534:659-665. doi: 10.1016/j.bbrc.2020.11.024. Epub 2020 Nov 22.
Apolipoprotein A4 (ApoA4) regulates lipid and glucose metabolism and exerts anti-inflammatory effects in atherogenesis and colitis. The present study explored the presumed protective role of ApoA4 in carbon tetrachloride (CCl4)-induced acute liver injury (ALI) in mice. The ALI model in wild type (WT), ApoA4 knock-out (ApoA4-KO) and ApoA4 transgenic (ApoA4-TG) mice was induced by a single intraperitoneal administration of CCl4. Liver and blood were harvested from mice to assess liver functions, immunohistological changes, immune cell populations and cytokine profiles. ApoA4 deficiency aggravated, and ApoA4 overexpression alleviated CCl4-inflicted liver damage by controlling levels of anti-oxidant enzymes. ApoA4 deletion increased the recruitment of monocytes/macrophages into the injured liver and upregulated the plasma levels of IL-6, TNF-α and MCP-1, but lower IL-10 and IFN-γ. ApoA4 over-expression rescued this effect and resulted in lower percentages of monocytes/macrophages and dendritic cells, the ratio of blood pro-inflammatory to anti-inflammatory monocytes and reduced plasma concentrations of IL-6, but enhanced IL-10 and IFN-γ. We propose ApoA4 as a potential new therapeutic target for the management of liver damage.
载脂蛋白 A4(ApoA4)在动脉粥样硬化和结肠炎的发生中调节脂质和葡萄糖代谢,并发挥抗炎作用。本研究探讨了 ApoA4 在小鼠四氯化碳(CCl4)诱导的急性肝损伤(ALI)中的假定保护作用。通过单次腹腔注射 CCl4 诱导野生型(WT)、ApoA4 敲除(ApoA4-KO)和 ApoA4 转基因(ApoA4-TG)小鼠的 ALI 模型。从小鼠中采集肝脏和血液,以评估肝功能、免疫组织化学变化、免疫细胞群和细胞因子谱。ApoA4 缺乏加重,而 ApoA4 过表达通过控制抗氧化酶水平减轻 CCl4 引起的肝损伤。ApoA4 缺失增加单核细胞/巨噬细胞向损伤肝脏的募集,并上调血浆中 IL-6、TNF-α 和 MCP-1 的水平,但降低 IL-10 和 IFN-γ。ApoA4 过表达挽救了这种作用,导致单核细胞/巨噬细胞和树突状细胞的百分比降低,血液前炎症/抗炎性单核细胞的比例降低,血浆中 IL-6 的浓度降低,但增加 IL-10 和 IFN-γ。我们提出 ApoA4 作为管理肝损伤的潜在新治疗靶点。